Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Open-label, Dose-ranging, Phase II Study to Evaluate the Efficacy and Safety in TG-2349 Combination With DAG181 (± Ribavirin) in Treatment naïve Subjects With Chronic Hepatic C Virus Genotype I Infection

NCT03593447 is registered in ClinicalTrials.gov with Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT03593447
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03593447 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Open-label, Dose-ranging, Phase II Study to Evaluate the Efficacy and Safety in TG-2349 Combination With DAG181 (± Ribavirin) in Treatment naïve Subjects With Chronic Hepatic C Virus Genotype I Infection
Lead sponsor
Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
March 15, 2018
Completion date
February 17, 2020
Enrollment
133 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatics c virus (hcv) genotype 1, cirrhosis, non-cirrhotic, treatment naïve